Monoclonal antibody successes in the clinic

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

[1]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[2]  D. Carson,et al.  Human lymphocyte hybridomas and monoclonal antibodies. , 1986, Advances in immunology.

[3]  C. Milstein,et al.  The hybridoma revolution: an offshoot of basic research. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[4]  R. Lacey,et al.  Monoclonal antiendotoxin agent HA-1A (Centoxin) , 1993, The Lancet.

[5]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[6]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[7]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Janice M Reichert,et al.  Therapeutic monoclonal antibodies: trends in development and approval in the US. , 2002, Current opinion in molecular therapeutics.

[9]  Janice M. Reichert,et al.  Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.

[10]  A. Pavlou,et al.  Monoclonal antibodies market , 2004, Nature Reviews Drug Discovery.

[11]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[12]  K. Sikora,et al.  Human monoclonal antibodies , 1982, Nature.

[13]  Wadih Arap,et al.  Hybridoma-free generation of monoclonal antibodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.